Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
July 7, 2025
In the News
Louis Lehot Assesses Deal Trends in Shifting Market
Foley & Lardner LLP partner Louis Lehot assessed dealmaking trends in the Law360 article, "PE Dealmakers Best-Suited To Cut Through M&A Challenges."
July 3, 2025
In the News
Christopher Swift Assesses CFIUS Involvement in Telecommunications Acquisition
Foley & Lardner LLP partner Christopher Swift shared insight on the Committe on Foreign Investment in the United States’ (CFIUS) involvement in a telecommunications transaction in The Capitol Forum article, “T-Mobile/UScellular: Team Telecom’s Deference Gives DOJ, FCC Flexibility to Penalize Buyer If It Violates Agreement.”
July 3, 2025
In the News
Louis Lehot Highlights Opportunities and Challenges for M&A Market
Foley & Lardner LLP partner Louis Lehot highlighted opportunities and challenges for the M&A market in the Law360 article, "Mid-Year M&A Deal Flow Suffers Amid Global Instability."